Bharat Biotech, the co-developer and manufacturer of India’s indigenous coronavirus disease vaccine, Covaxin, on Thursday announced a revised selling price of ₹400 per dose, from the earlier ₹600, for state governments.
The vaccine manufacturer’s decision to slash the price by 33% came a a day after another Covid-19 vaccine manufacturer, Serum Institute of India (SII), which makes the Oxford-AstraZeneca vaccine under the brand name Covishield in India, reduced its selling price to states to ₹300 from ₹400.
“Bharat Biotech is deeply concerned with the critical pandemic circumstances that India is facing at this time. Recognising the enormous challenges to the public health care system, we have made Covaxin available to state governments at a price of ₹400 per dose,” the company said in a statement.
“We wish to be transparent in our approach to pricing which was determined by internally funded product development, several operationally intensive BSL-3 manufacturing facilities (the first of its kind in our country) and clinical trials. We wish to champion innovation in India and our commitment to public health is absolute,” the statement added.